Antimicrobial Pharmacodynamics
|
|
- Erik Howard
- 5 years ago
- Views:
Transcription
1 Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU
2 Objectives Become familiar with PD parameters what they tell us how to measure them Identify the PD parameter associated with efficacy and/or resistance prevention for a variety of antibiotics Identify dosing methods that may be used to optimize the PD of various antibiotics
3 Concentrations in Tissues & Body Fluids Pharmacologic and Toxicologic Effects Dosing Regimen Concentration in Serum Concentrations at Site of Infection Antimicrobial Effect Craig WA. Clin Infect Dis 1998;26:1-12.
4 Elements of PD Susceptibility data indicates potency, but not the time course of antibacterial activity Pharmacokinetic data indicates the time course of antibiotic concentrations, but not the killing activity of an antibiotic Integration of susceptibility results and PK data allows us to quantify antibiotic activity over time
5 Susceptibility Testing MIC (minimum inhibitory concentration) Measures lowest antimicrobial concentration that inhibits bacterial growth Expressed in a standard numerical scheme that incorporates doubling concentrations e.g., 0.25 mcg/ml, 0.5 mcg/ml, 1 mcg/ml, etc. MIC 90 versus MIC 50
6 MIC Analysis: Microdilution
7 MIC Analysis: Microdilution
8 MIC Analysis: Etest
9 MIC Analysis: Etest
10 Breakpoints Interpretive Standards for Pseudomonas aeruginosa Antimicrobial MIC (mcg/ml) Interpretive Standard S I R Piperacillin Ceftazidime Imipenem Aztreonam Gentamicin Ciprofloxacin Chloramphenicol
11 MICs for Fluoroquinolones Against Streptococcus pneumoniae Fluoroquinolone Year MIC 90 % R Ciprofloxacin* Levofloxacin Gatifloxacin Moxifloxacin n/a n/a n/a *Breakpoint values have not been assigned for ciprofloxacin Brueggemann AB et al. Antimicrob Agents Chemother 2002;46:
12 In vitro Activity Against 8,352 Respiratory Isolates of Streptococcus pneumoniae SENTRY Program, MIC (mg/l) Antibiotic % R MIC 50 MIC 90 Penicillin Amoxicillin Amoxicillin/clavulanate Cefpodoxime Erythromycin Clindamycin Tetracycline TMP/SMX Rifampin Levofloxacin Vancomycin Hoban DJ et al. Clin Infect Dis 2001;32(Suppl 2):81-93.
13 Type: Gram Negative Susceptibility Organism: Klebsiella pneumoniae Antibiotic Result Ampicillin >=32 R Ampicillin/sulbactam >=32 R Cefazolin 32 R Ceftriaxone 4 R Ciprofloxacin 2 I Gentamicin >=16 R Levofloxacin 1 S Piperacillin 64 R Piperacillin/tazobactam Ticarcillin/clavulanate Tobramycin <=4 S 16 R >=16 R
14 What Do PD Studies Tell Us? 1. For a given antibiotic, the PD parameter that must be optimized in order to obtain the outcome of interest 2. The threshold or target value (of the above PD parameter) that must be attained in order to obtain the outcome of interest
15 Concentration-Dependent Killing Killing activity increases with an increase in antibiotic concentration Maximal killing achieved at 8-10 x MIC, AUC/MIC=30, or AUC/MIC=125 Aminoglycosides, fluoroquinolones
16 Time-Dependent Killing Killing activity increases with an increase in time spent above the MIC Maximal killing achieved when T > MIC is 60-70% of dosing interval Penicillins, cephalosporins, macrolides
17 Concentration-Kill Relationship 8 Ciprofloxacin 8 Ticarcillin 7 7 1/4x MIC log 10 CFU/mL (Bacterial Count) /4x MIC x MIC 4x MIC 16x MIC 64x MIC 3 16x MIC 4x MIC 1x MIC x MIC time (hr) Craig WA. Clin Infect Dis 1998;26:1-12.
18 Post-Antibiotic Effect (PAE) Describes persistent suppression of bacterial growth after antimicrobial exposure Implies that the effect is due to prior exposure rather than persistent inhibitory concentrations Usually measured in vitro Clinical significance is uncertain
19 Characteristics of PAE PAE is dependent on: Antibiotic Antibiotic concentration Duration of exposure Bacterial species: Gram + > Gram -
20 PD Parameters C max 1) C max /MIC 2) AUC/MIC 3) Time > MIC ABX Concentration AUC Time MIC C min Time Craig WA. Clin Infect Dis 1998;26:1-12.
21 Pattern of Activity Antibiotics Goal of Therapy PD Parameter Type 1 Concentrationdependent killing Prolonged persistent effects Aminoglycosides Fluoroquinolones Maximize concentrations C max /MIC AUC/MIC Type 2 Time-dependent killing Minimal persistent effects Beta-lactams Erythromycin Linezolid Maximize duration of exposure T>MIC Type 3 Time-dependent killing Moderate persistent effects Azithromycin Clindamycin Tetracyclines Maximize amount of drug AUC/MIC Gunderson BW et al. Pharmacotherapy 2001;21:302S-318S.
22 Evaluating Antimicrobial PD 1. Determine the PD parameter that correlates with the outcome of interest 2. Determine the value of that PD parameter that must be attained to ensure the outcome of interest
23 Step 1 Determine the PD parameter that correlates with the outcome of interest
24 Measuring PD Parameters In vitro models Animal models Human studies
25 Dose Fractionation Simulation of adequate number of unique PK profiles to allow statistically significant determination of PD Interval q4h q6h q8h q12h q24h Dose 100 mg 200 mg 300 mg 400 mg
26 In vitro Models
27 In vitro Models
28 Typical Results: In vitro Models Bacterial Count (CFU/mL) Dose 1 Dose 2 Dose 3 Dose Dose time (hr)
29 Animal Models Rabbit Model of Endocarditis Mouse Thigh Infection Model
30 Typical Results: Animal Models GC 10 9 Bacterial Count (CFU/thigh) or Mortality Dose 1 Dose 2 Dose 3 Dose Dose time (hr)
31 Human Studies
32 Scenario #1 Craig WA. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice
33 Scenario #2 Craig WA. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice
34 Step 2 Determine the value of that PD parameter that must be attained to ensure the outcome of interest
35 Relationship Between 24-h AUC/MIC and Mortality in Animals for Fluoroquinolones against Gram (-) Bacilli Andes D et al. Int J Antimicrob Agents 2002;19:261-8.
36 Relationship Between 24-h AUC/MIC and Mortality in Animals for Fluoroquinolones against S. pneumoniae Andes D et al. Int J Antimicrob Agents 2002;19:261-8.
37 Relationship Between Time > MIC and Mortality in Animal Models of S. pneumoniae with β-lactams Craig WA. Clin Infect Dis 1998;26:1-10.
38 Relationship Between Time > MIC and Bacterial Eradication in Otitis Media and Maxillary Sinusitis Craig WA. Clin Infect Dis 1998;26:1-12.
39 % Patients with Positive Clinical and Microbiologic Outcome (74 patients treated with ciprofloxacin mg IV q8h) 100 Eradication Cure % AUC/MIC < 125 AUC/MIC > 125 Forrest A et al. Antimicrob Agents Chemother 1993;37:
40 Unresolved Issues Endpoint targeted Site of infection Effect of protein binding Immune status Organism Combination therapy
41 PD Parameters and Resistance Comparatively little research performed Resistance is difficult to obtain in a randomized clinical trial Prevention of resistance may be more important than maximization of killing
42 Application of PD 1. How effective will a specific dose of an antibiotic be in a given patient? 2. What is the highest MIC that will allow attainment of the PD goal? 3. Can we increase the dose of an antimicrobial to achieve the PD goal? 4. Of available options for a given infection, will a particular agent be able to attain the PD goal?
43 Beta-lactams
44 Beta-lactam PD Longer T > MIC improves efficacy 30-40% T > MIC for bacteriostatic effect 60-70% T > MIC for maximum killing
45 Should We Dose More Often? Beta-lactam Concentration MIC Time 24h
46 PD Profile of Piperacillin-Tazobactam MIC (mg/l) T>MIC (%) 4.5 gm q8h gm q6h Pathogens H. influenzae Proteus spp MSSA E. coli S. pneumoniae K. pneumoniae Enterobacter spp. Citrobacter spp. Serratia spp P. aeruginosa n=12 Kim M-K et al. Pharmacotherapy 2002;22:
47 Continuous Infusion Dosing β-lactam Concentration MIC Time 24h
48 Likelihood of Achieving Pharmacodynamic Target (Monte Carlo Simulation in 1000 Patients) Cefepime Dose Cl Cr (ml/min) 2g q12h (30 min) (infusion time) 2g q8h (30 min) 2g q12h (6h) 4g q24h (24h) Tam VH et al. Pharmacotherapy 20030;23:291-5.
49 PD of Cephalosporins in Otitis Media Caused by S. pneumoniae 100 Cefuroxime T>MIC (%) Bacteriologic Persistence % Cefaclor PSSP PISP PRSP Cefuroxime Cefaclor PSSP PISP/PRSP Dagan R et al. Lancet 2002;2:
50 Fluoroquinolones
51 Fluoroquinolone PD AUC/MIC determines efficacy C max /MIC determines resistance prevention? AUC/MIC > 125 for Gram - AUC/MIC > for Gram +
52 FQ PD S. pneumoniae FQ MIC 90 C max C max /MIC AUC AUC/MIC Ciprofloxacin Gatifloxacin Levofloxacin Moxifloxacin Doern GV. Clin Infect Dis 2001;33 Suppl 3:
53 FQ Resistance in S. pneumoniae Reference Wortmann meningitis not reported 1/1 Empey CAP not reported 1/1 Urban CAP 1/2 2/2 Weiss HAP not reported 16/16 Kays CAP 1/1 1/1 Davidson CAP 4/4 4/4 Ross CAP 1/1 1/1 Anderson 2003 n 4 (10 episodes) Disease CAP Prior FQ 10/10 Resistance? 6/10
54 FQ PD P. aeruginosa 74 patients with severe infections Ciprofloxacin 200 mg mg IV q8h Patient-specific PD parameters and pathogen MICs used to correlate PD and outcome Outcomes measured: daily cultures, time to organism eradication Forrest A et al. Antimicrob Agents Chemother 1993;37:
55 FQ PD P. aeruginosa Factors Related to Positive Clinical and Microbiologic Outcome Univariate Analysis AUC/MIC > 125 MIC < 0.5 C max / MIC > 4 C min / MIC > 1 T > MIC > 33% Multivariate Analysis AUC/MIC > 125 Forrest A et al. Antimicrob Agents Chemother 1993;37:
56 FQ PD P. aeruginosa 100 Eradication Cure % AUC/MIC < 125 AUC/MIC > 125 Forrest A et al. Antimicrob Agents Chemother 1993;37:
57 FQ PD P. aeruginosa For susceptible bacteria (MIC < 0.125): standard FQ dosing likely to achieve AUC/MIC > 250 dose reduction a possibility? For less susceptible bacteria (MIC 0.25): more aggressive dosing may be required combination therapy? Forrest A et al. Antimicrob Agents Chemother 1993;37:
58 Aminoglycosides
59 Aminoglycoside PD Higher C max improves efficacy PAE allows longer dosing interval Lower C min lessens toxicity Longer dosing interval may limit development of bacterial resistance
60 Extended Interval Dosing C max 8-10x MIC AMG Concentration MIC Time 24h
61 Aminoglycoside Dosing Strategies Divided Daily Dosing Extended Interval mg/kg q12-72h disease-targeted C max C max = ~ 6-10 mg/l C min < 1 mg/l 4-7 mg/kg q24h PD-targeted C max C max = ~ mg/l C min ~ 0 mg/l
62 Limitations of Extended Interval Dosing Renal function must be good Cl Cr 50 ml/min usually required Appropriate patient populations Target concentrations still under debate Institution-specific nomograms
63 Extended-Interval AMG Dosing Protocols Calculate Cl Cr, IBW / ABW / dosing weight Determine target peak based on bacterium probably should also consider infection Dose: 4-7 mg/kg q24h 4-5 mg/kg = peak ~ mg/l 6-7 mg/kg = peak ~ mg/l TDM: peak? 8h concentration?
64 Meta-Analysis of 26 Studies of EIAD Difference in Clinical Response (± 95% CI) -40% -20% 0% 20% 40% 60% (sub-mean 1) Study (sub-mean 2) (mean) Boselli E et al. Crit Care Med 2003;31:
65 Meta-Analysis of 26 Studies of EIAD Difference in Microbiologic Response (± 95% CI) -40% -20% 0% 20% 40% 60% (sub-mean 1) Study (sub-mean 2) (mean) Boselli E et al. Crit Care Med 2003;31:
66 EIAD: Results Several thousand patients evaluated Few comparative trials published Trend towards increased efficacy Trend towards decreased nephrotoxicity Uncertain effect on ototoxicity
67 Clinician-Operated PD Programs
68 PD Optimization Programs 1. Empiric therapy (traditional approach) 2. Isolate pathogen, determine MIC 3. PK analysis 4. Adjust dose or interval using PD Scaglione F. Intl J Antimicrob Agents 2002;257:
69 Impact of a PD Intervention Program Focusing on Aminoglycosides, Fluoroquinolones, and Beta-lactams in Patients with Severe Infection LOS a Failure Mortality PD Analyzed 11 days (7-16) 39/223 (17.5%) 11 (4.9%) PD Not Analyzed 16 days (9-23) 147/457 (31.9%) 46 (10.1%) a duration of hospitalization after infection identified n=680, October 2000 April 2001 Scaglione F. Intl J Antimicrob Agents 2002;257:
Introduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationPharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient
Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationAntibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals
Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Tom Dilworth, PharmD Aurora Health Care thomas.dilworth@aurora.org Objectives Describe the pharmacokinetics and pharmacodynamics
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationparameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an
Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationCombating Antimicrobial Resistance with Extended Infusion Beta-lactams. Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationDisclosure. Objectives. Combating Antimicrobial Resistance with Extended Infusion Beta-lactams
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationGeneral Infectious Disease Concepts/Resources
General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationUse of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More information